Literature DB >> 17456662

Prolongation of intrathecal and sciatic nerve blocks using a complex of levobupivacaine with maltosyl-beta-cyclodextrin in rats.

Ken Karashima1, Masahiko Taniguchi, Tadashi Nakamura, Mayumi Takasaki, Kanako Matsuo, Mitsuru Irikura, Tetsumi Irie.   

Abstract

BACKGROUND: We used a cyclodextrin-based drug delivery system, consisting of levobupivacaine complexed with maltosyl-beta-cyclodextrin (G2-beta-CD), in spinal and sciatic nerve blocks in rats to investigate prolongation of the local anesthetic effect.
METHODS: Rats were assigned to four groups (n = 6 in each) and received intrathecally 30 microL of 1% levobupivacaine complexed with 0 (control), 50, 100, or 200 mM of G2-beta-CD. Muscle tone and tail flick latency were studied after intrathecal administration. Four more groups (n = 6) of rats received a sciatic nerve block with 0.5% or 1% levobupivacaine complexed with either 0 or 100 mM of G2-beta-CD. The time course of changes in proprioception, motor function, and nociception after circumferential subcutaneous administration to the sciatic nerve was examined.
RESULTS: With the intrathecal block, all rats stopped tail movement immediately after injection of the local anesthetic. The mean time to recovery of muscle tone with 1% levobupivacaine complexed with 100 mM (80.0 +/- 8.9 min) and 200 mM (91.7 +/- 7.0 min) of G2-beta-CD was significantly longer than that of the control group (38.3 +/- 3.1 min), but tail flick latency was not prolonged. With the sciatic nerve block, all rats were temporarily immobilized after levobupivacaine injection. The anesthetic effects of 0.5% levobupivacaine with 100 mM of G2-beta-CD were twice as long as those for 0.5% levobupivacaine alone, and those of 1% levobupivacaine with 100 mM of G2-beta-CD were 1.4 times longer than those for 1% levobupivacaine alone.
CONCLUSIONS: The complex of levobupivacaine with G2-beta-CD prolonged the anesthetic effect of levobupivacaine in both intrathecal and sciatic nerve blocks in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456662     DOI: 10.1213/01.ane.0000260309.15034.52

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

Review 1.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

2.  Local toxicity from local anesthetic polymeric microparticles.

Authors:  J Brian McAlvin; Gally Reznor; Sahadev A Shankarappa; Cristina F Stefanescu; Daniel S Kohane
Journal:  Anesth Analg       Date:  2013-03-04       Impact factor: 5.108

3.  Drug delivery systems for prolonged duration local anesthesia.

Authors:  Claudia M Santamaria; Alan Woodruff; Rong Yang; Daniel S Kohane
Journal:  Mater Today (Kidlington)       Date:  2016-12-20       Impact factor: 31.041

4.  In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.

Authors:  Nushrat Yasmin; Yoichi Ishitsuka; Madoka Fukaura; Yusei Yamada; Shuichi Nakahara; Akira Ishii; Yuki Kondo; Toru Takeo; Naomi Nakagata; Keiichi Motoyama; Taishi Higashi; Yasuyo Okada; Junichi Nishikawa; Atsushi Ichikawa; Daisuke Iohara; Fumitoshi Hirayama; Katsumi Higaki; Kousaku Ohno; Muneaki Matsuo; Tetsumi Irie
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

Review 5.  Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches.

Authors:  Ksenia Mitusova; Oleksii O Peltek; Timofey E Karpov; Albert R Muslimov; Mikhail V Zyuzin; Alexander S Timin
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

6.  Adjuvants to local anesthetics: Current understanding and future trends.

Authors:  Amlan Swain; Deb Sanjay Nag; Seelora Sahu; Devi Prasad Samaddar
Journal:  World J Clin Cases       Date:  2017-08-16       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.